Ad
related to: who should not take glimepiride for diabetes medication dosage instructionsexplorefrog.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. [ 1 ] [ 2 ] It is regarded as a second-line option compared to metformin , due to metformin's well-established safety and efficacy. [ 1 ]
Drugs used in diabetes treat diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
The dose is usually started low and tapered gradually. Some of the common side effects of the medication is nausea, vomiting and diarrhea. Patients with a family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 should not be prescribed the drug may increase the risk of developing cancer. [37]
There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight loss. ... The most common side effects of GLP-1 medications are ...
The most common side effects include upper respiratory tract infections (such as colds), hypoesthesia (reduced sense of touch), bone fractures, weight gain, dizziness, flatulence (gas) and edema (swelling).
Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). They are found in raw plants/herbs such as cinnamon and bacteria (containing the inhibitor acarbose ).
SPOILERS BELOW—do not scroll any further if you don't want the answer revealed. The New York Times. Today's Wordle Answer for #1275 on Sunday, December 15, 2024.
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. [25]
Ad
related to: who should not take glimepiride for diabetes medication dosage instructionsexplorefrog.com has been visited by 10K+ users in the past month